Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~  * Previously treated disease~* Candidate for high-dose chemotherapy with melphalan and autologous stem cell transplantation~* No definite evidence of myelodysplasia on pretreatment bone marrow by morphology or by chromosome analysis (e.g., monosomy 7)~  * Chromosome abnormalities from the myeloma clone allowed~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 2.0 mg/dL~* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~* Creatinine ≤ 2 times ULN~* LVEF ≥ 45%~* Corrected pulmonary diffusion capacity ≥ 50%~* No uncontrolled infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other active malignancy (with the exception of nonmelanoma skin cancer) that requires myelosuppressive chemotherapy or radiation therapy~* No HIV positivity~PRIOR CONCURRENT THERAPY:~* More than 3 weeks since prior myelosuppressive chemotherapy, except cyclophosphamide pulsing for stem cell collection)~* No other concurrent immunotherapy, radiotherapy, chemotherapy or antimyeloma therapy~* Concurrent chronic corticosteroids at doses of prednisone ≤ 20 mg per day (or equivalent) allowed~* Concurrent adjuvant hormonal therapy (e.g., tamoxifen citrate or leuprolide acetate) allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab + Zevalin (Type: EXPERIMENTAL): Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.

Based on this trial design, predict the completion outcome and termination type (if applicable).